2026-01-23 - Analysis Report
**Report: Ventas, Inc. (VTR)**

**Company Overview**: Ventas is a healthcare real estate investment trust (REIT) that owns and operates a portfolio of high-quality healthcare facilities.

**Return Comparison with S&P 500 (VOO)**

- Cumulative Return of Review Stock: 106.02%
- Cumulative Return of Comparison Stock (S&P 500, VOO): 92.53%
- Divergence (max: 35.10, min: -54.60, current: 17.80, relative divergence: 80.70%)

**Alpha, Beta Analysis**

| Year    | CAGR | MDD  | Alpha | Beta | Cap(B) |
|---------|------|------|-------|------|--------|
| 2016-2018 | 5.0% | 17.1% | 1.0% | 0.4 | 27.5B  |
| 2017-2019 | -10.0% | 22.6% | -27.0% | 0.2 | 27.1B  |
| 2018-2020 | 39.0% | 40.3% | 18.0% | 1.3 | 23.0B  |
| 2019-2021 | 10.0% | 40.3% | -33.0% | 1.4 | 24.0B  |
| 2020-2022 | 18.0% | 36.3% | 20.0% | 1.3 | 21.2B  |
| 2021-2023 | 18.0% | 33.8% | 17.0% | 0.8 | 23.4B  |
| 2022-2024 | 41.0% | 33.8% | 22.0% | 0.7 | 27.7B  |
| 2023-2025 | 88.0% | 15.2% | 26.0% | 0.5 | 36.4B  |

**Recent Stock Price Fluctuations**

* Close: $76.58
* Last-market: {'price': 76.58, 'previousClose': 77.78, 'change': -1.54}
* 5-day SMA: $77.58
* 20-day SMA: $77.36
* 60-day SMA: $77.54

The sharp decline in the last market indicates a fluctuation issue (sharp rebound, sharp decline).

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence**

* Market Risk Indicator (MRI): 0.90 (High Investment Recommended)
* RSI: 44.98
* PPO: 0.11
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: High (MRI 0.90)
* Recent (20 days) relative divergence change: 11.20 (+): improving
* 7-day Rank change: 18 (+): rank up
* 7-day Dynamic Expected Return change: 0.60 (+): improving
* Expected Return (%): -3.50%

**Recent News & Significant Events**

* Universal Beteiligungs und Servicegesellschaft mbH Grows Stock Position in Ventas, Inc. $VTR - MarketBeat (link)
* Ventas Stock Gains 10.9% in Three Months: Will it Continue to Rise? - Zacks Investment Research (link)
* How Fresh Bullish Analyst Coverage Will Impact Ventasâ€™ (VTR) Long-Term Earnings Narrative - simplywall.st (link)
* Ventas' quarterly earnings preview: What you need to know - MSN (link)
* VTR Stock Falls -5.2% With 7-day Losing Spree On C-Suite Stock Sales - Trefis (link)
* Is Ventas (VTR) The Best REIT Dividend Stock to Buy for Non-AI Trade? - Yahoo Finance (link)

**Analyst Opinions**

* Analyst Consensus:
	+ Key: Buy
	+ Mean (1=StrongBuy~5=Sell): 1.52 (~Buy)
	+ Opinions: 20
	+ Target Price (avg/high/low): 85.65 / 94.00 / 75.00

**Recent Earnings Analysis**

| Date       | EPS | Revenue |
|------------|-----|---------|
| 2025-10-30 | 0.14 | 1.49 B$ |
| 2025-07-31 | 0.15 | 1.42 B$ |
| 2025-05-01 | 0.11 | 1.36 B$ |
| 2024-10-31 | 0.05 | 1.24 B$ |
| 2025-04-01 | 0.05 | 1.24 B$ |

The earnings growth is slow, with EPS increasing from 0.05 to 0.14 in the last two quarters.

**Financial Information: Revenue and Profitability**

| Quarter  | Revenue | Profit Margin |
|----------|---------|---------------|
| 2025-09-30 | $1.49B | 41.58%       |
| 2025-06-30 | $1.42B | 41.80%       |
| 2025-03-31 | $1.36B | 42.15%       |
| 2024-12-31 | $1.29B | 42.42%       |
| 2024-09-30 | $1.24B | 42.17%       |

The revenue growth is steady, with a slight decline in profit margin.

**Financial Information: Capital and Profitability**

| Quarter  | Equity | ROE |
|----------|---------|-----|
| 2025-09-30 | $12.36B | 0.53% |
| 2025-06-30 | $11.53B | 0.59% |
| 2025-03-31 | $11.47B | 0.41% |
| 2024-12-31 | $10.77B | 0.53% |
| 2024-09-30 | $9.76B | 0.20% |

The equity growth is steady, with a slight decline in ROE.

**Comprehensive Analysis (Summary of previous items)**

Ventas, Inc. (VTR) is a healthcare real estate investment trust (REIT) with a strong portfolio of high-quality healthcare facilities. The company's return on investment is higher than the S&P 500, indicating a higher level of risk. The RSI, PPO, and Delta_Previous_Relative_Divergence indicators show a high level of risk, and the expected return is negative. The recent news and significant events indicate a mix of positive and negative trends. The analyst opinions suggest a strong buy with a high target price. The earnings growth is slow, and the revenue growth is steady with a slight decline in profit margin. Overall, the investment in Ventas, Inc. (VTR) is considered high-risk with a possibility of negative returns.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.